IAS
RANI icon

Insigneo Advisory Services’s Rani Therapeutics RANI Stock Holding History

Insigneo Advisory Services’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-47,500
Closed -$23.7K – 823
2025
Q3 		$23.7K Hold
47,500
– – ﹤0.01% 702
2025
Q2 		$24.4K Hold
47,500
– – ﹤0.01% 620
2025
Q1 		$59.9K Hold
47,500
– – 0.01% 563
2024
Q4 		$65.1K Buy
+47,500
New +$99.8K 0.01% 560

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Insigneo Advisory Services's RANI Position: Q4 2025 in Review

Insigneo Advisory Services sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 47,500 shares — an estimated $23.7K sold.

Insigneo Advisory Services first reported a position in RANI in Q4 2024 and held it in 4 quarters. The position peaked at $65.1K in Q4 2024. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • Insigneo Advisory Services reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Insigneo Advisory Services sold 47,500 Rani Therapeutics shares in Q4 2025, an estimated $23.7K.
  • Insigneo Advisory Services first reported a position in Rani Therapeutics in Q4 2024 and held it in 4 quarters.
  • Insigneo Advisory Services's Rani Therapeutics position peaked at $65.1K in Q4 2024.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on Insigneo Advisory Services's 13F filing for Q4 2025, filed 12 Feb 2026.